INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 319 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.64 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $356,452 | -20.4% | 11,273 | +2.7% | 0.00% | 0.0% |
| Q2 2023 | $447,724 | +21.3% | 10,979 | +10.9% | 0.00% | 0.0% |
| Q1 2023 | $369,010 | -0.8% | 9,901 | -7.1% | 0.00% | 0.0% |
| Q4 2022 | $372,032 | -44.3% | 10,663 | -10.7% | 0.00% | -33.3% |
| Q3 2022 | $668,000 | +21.2% | 11,943 | +12.2% | 0.00% | 0.0% |
| Q2 2022 | $551,000 | -23.3% | 10,642 | +7.8% | 0.00% | 0.0% |
| Q1 2022 | $718,000 | -44.4% | 9,875 | -9.6% | 0.00% | -40.0% |
| Q4 2021 | $1,292,000 | -12.6% | 10,925 | -0.9% | 0.01% | -28.6% |
| Q3 2021 | $1,479,000 | -7.9% | 11,026 | +11.1% | 0.01% | 0.0% |
| Q2 2021 | $1,606,000 | +90.3% | 9,920 | -5.7% | 0.01% | +75.0% |
| Q1 2021 | $844,000 | -41.6% | 10,520 | -60.4% | 0.00% | -33.3% |
| Q4 2020 | $1,444,000 | +167.4% | 26,545 | -2.2% | 0.01% | +200.0% |
| Q3 2020 | $540,000 | -4.6% | 27,145 | +0.8% | 0.00% | -33.3% |
| Q2 2020 | $566,000 | +69.5% | 26,920 | -1.3% | 0.00% | +50.0% |
| Q1 2020 | $334,000 | – | 27,270 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,216,340 | $62,958,000 | 7.04% |
| Discovery Value Fund | 584,483 | $30,253,000 | 6.33% |
| MPM BioImpact LLC | 299,409 | $15,497,000 | 4.30% |
| ARK Investment Management | 9,514,580 | $439,003,000 | 2.60% |
| Elmwood Wealth Management, Inc. | 67,899 | $3,514,000 | 2.00% |
| Nikko Asset Management Americas, Inc. | 2,781,136 | $141,143,000 | 1.74% |
| Avidity Partners Management LP | 1,125,194 | $58,240,000 | 1.34% |
| Merlin Capital, Inc | 12,174 | $630,000 | 1.26% |
| Atlas Venture Associates IX, LLC | 10,000 | $518,000 | 1.18% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $5,768,000 | 1.16% |